Topical nano-encapsulated cyclosporine formulation for atopic dermatitis treatment: Topical cyclosporine NCs for AD

Citation:

A. Badihi, M. Frušić-Zlotkin, Y. Soroka, S. Benhamron, T. Tzur, T. Nassar, and S. Benita. 2020. “Topical nano-encapsulated cyclosporine formulation for atopic dermatitis treatment: Topical cyclosporine NCs for AD.” Nanomedicine: Nanotechnology, Biology, and Medicine, 24.

Abstract:

Systemic cyclosporine A (CsA) therapy shows efficacy in the treatment of recalcitrant severe atopic dermatitis (AD) but elicits severe side-effects. Thus, a topical formulation of CsA nanocapsules (NCs), able to potentially bypass these drawbacks, was developed. CsA-NCs were shown to enhance drug penetration into the various layers of porcine ear skin. Furthermore, the encapsulated CsA was biologically active, as shown in vitro on mouse splenocytes, reflected by inhibition of both cell proliferation and of interleukin (IL)-2 secretion. Ex-vivo efficacy was demonstrated on human skin organ culture by markedly reducing pro-inflammatory cytokines secretion. Finally, CsA-NCs topical formulation elicited improved efficacy in terms of better preservation of the skin barrier integrity, a decrease of the systemic pro-inflammation markers and reduced skin inflammation. The overall results suggest that this original topical platform may provide a novel therapeutic tool of clinical significance compared to the existing topical therapeutic drugs in AD. © 2019 Elsevier Inc.

Notes:

cited By 2
See also: Simon Benita
Last updated on 02/09/2021